Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | MSGV1-PSCA-8T28Z |
| Synonyms | |
| Therapy Description |
MSGV1-PSCA-8T28Z are autologous gamma delta T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting PSCA, containing a CD8 alpha hinge and transmembrane domain, CD28 costimulatory domain, and CD3zeta signaling domain, which potentially induce cytotoxicity against PSCA-expressing tumor cells and inhibit tumor growth (PMID: 37134157). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| MSGV1-PSCA-8T28Z | Autologous MSGV1-PSCA-8T28Z gdCAR T-cells | PSCA Immune Cell Therapy 3 | MSGV1-PSCA-8T28Z are autologous gamma delta T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting PSCA, containing a CD8 alpha hinge and transmembrane domain, CD28 costimulatory domain, and CD3zeta signaling domain, which potentially induce cytotoxicity against PSCA-expressing tumor cells and inhibit tumor growth (PMID: 37134157). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06193486 | Phase I | MSGV1-PSCA-8T28Z Cyclophosphamide + Fludarabine | Autologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPC | Recruiting | USA | 0 |